Shopping Cart
Remove All
Your shopping cart is currently empty
Pasotuxizumab (BAY 2010112) is a bispecific T-cell engager (BiTE) targeting PSMA and CD3, with dissociation constants (K D) of 47.0 nM for PSMA and 9.4 nM for CD3. It is used in the study of metastatic castration-resistant prostate cancer (mCRPC) [1] [2].
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $373 | 2-4 weeks | 2-4 weeks | |
| 5 mg | $968 | 2-4 weeks | 2-4 weeks | |
| 10 mg | $1,550 | 2-4 weeks | 2-4 weeks |
| Description | Pasotuxizumab (BAY 2010112) is a bispecific T-cell engager (BiTE) targeting PSMA and CD3, with dissociation constants (K D) of 47.0 nM for PSMA and 9.4 nM for CD3. It is used in the study of metastatic castration-resistant prostate cancer (mCRPC) [1] [2]. |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Cas No. | 1442657-12-6 |
| Storage | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.